Which oral steroids should never be combined with Methandienone due to liver risk?

No second 17α-alkylated oral should be run concurrently with Methandienone. Compounds such as Oxymetholone, Stanozolol, or Oxandrolone stress the same hepatic enzyme pathways, and hepatology case series consistently identify multi-alkylated-oral stacks as a distinct, higher-risk category. Running them sequentially — not simultaneously — is the standard risk-reduction approach cited in sports-medicine literature.

Does alcohol consumption interact negatively with Methandienone tablets?

Yes — alcohol is a pharmacologically active unfavorable co-administration with Methandienone. Both ethanol and 17α-alkylated compounds compete for hepatic oxidative metabolism, raising intrahepatic oxidative load beyond single-agent predictions. The WHO's 2020 liver-disease guidelines list concurrent alcohol use as a contraindication amplifier for hepatotoxic pharmaceuticals, which includes orally alkylated androgens.

Can prescription medications like antifungals or statins be taken alongside Methandienone safely?

This combination carries measurable added risk. Azole antifungals inhibit CYP3A4, slowing Methandienone clearance and raising systemic exposure; statins independently elevate liver enzymes via hepatic mechanisms distinct from but additive to 17α-alkylation stress. Practitioners using either drug class should consult a physician and monitor ALT, AST, and GGT at closer intervals than during Methandienone-only protocols.

How many tablets does the Knoll Danabol 500 pack contain, and how are they packaged for long-term storage?

The pack contains exactly 500 tablets at 10 mg Methandienone each. Knoll Pharmaceuticals formats this supply in a configuration designed to protect tablet integrity across the extended storage periods that a 500-count volume requires — important because API degradation from humidity or heat would compromise dose accuracy at any point in the supply window.

Can the 10 mg tablets be split for sub-10 mg dosing within an unfavorable-combination avoidance protocol?

Splitting is mechanically possible but pharmacologically imprecise. HPLC content-uniformity testing applies to the intact tablet; a split half carries an unmeasured variance that matters most when the combination context already demands precise exposure management. Where sub-10 mg intake is the goal to reduce combined hepatic load, reducing or discontinuing the tablet is preferable to fractioning it. (2) angle_used

Verified Manufacturer

Knoll Pharmaceuticals

Danabol 500 10mg/tab 500 Tabletten by Knoll Pharmaceuticals

Name: Danabol 500 10mg/tab 500 Tablets by Knoll Pharmaceuticals
Brand: Knoll Pharmaceuticals
SKU: ORA-METH-KNO-014
Price: 85.00 EUR
Availability: InStock

Knoll Pharmaceuticals Danabol 500 delivers Methandienone at 10 mg per tablet across a 500-tablet supply — a format that demands careful attention to what this compound should not be paired with, because its hepatotoxic, cardiovascular, and hormonal profile interacts adversely with a distinct set of co-administered agents. Combining Methandienone with other 17α-alkylated orals, nephrotoxic compounds, or potent CYP-inhibiting substances is a recognized risk multiplier documented in clinical hepatology and sports-medicine literature. Quality assurance at Knoll Pharmaceuticals is built on pharmaceutical-grade tablet compression with HPLC content-uniformity verification; every production batch is traceable from raw API through finished tablet.

€85.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

500-tablet supply provides continuity across extended, carefully structured protocols without mid-cycle resupply interruptions.
Uniform 10 mg tablet strength enables precise daily load adjustment when combination risk monitoring prompts a step-down.
Knoll Pharmaceuticals applies HPLC content-uniformity testing to confirm per-tablet API accuracy — critical when dose precision determines combined hepatic safety.
Single-active-ingredient formulation eliminates hidden co-ingredients that could introduce undisclosed CYP-interaction risk.
Pharmaceutical-grade tablet compression technology supports consistent disintegration and absorption across the full 500-tablet lot.
Traceable batch documentation allows practitioners to cross-reference production records against monitoring blood-work findings.

Phase	dosage	Note
Baseline (pre-start)	0 mg — assessment only	Establish ALT, AST, GGT, and lipid baseline; confirm no concurrent hepatotoxic agents (statins, azoles, alcohol) are present before first tablet.
Low-load entry (weeks 1–2)	10 mg/day (1 tablet)	Single-alkylated-oral exposure only; no second 17α-alkylated compound. Monitor for enzyme response before any upward adjustment.
Maintenance window (weeks 3–5)	20 mg/day (2 tablets)	Continue single-oral policy. If a second aromatizing injectable is present, aromatase inhibitor use becomes non-optional to prevent additive estrogenic load.
Taper exit (week 6)	10 mg/day (1 tablet)	Reduce dose, not combination breadth — do not add a new compound during the taper. Recheck ALT/AST before stopping.
Post-cycle washout	0 mg — PCT phase	No second alkylated oral for a minimum of four weeks after last Methandienone tablet. SERM-based PCT governed by injectable half-lives.

Key takeaways

Avoid stacking two 17α-alkylated orals simultaneously to limit hepatic stress.
Discontinue Methandienone if ALT exceeds twice the upper reference range.
Eliminate alcohol entirely during any Methandienone-containing protocol.
Monitor serum liver enzymes before the first tablet and every four weeks.
Separate sequential orals by a washout window before switching compounds.

Methandienone and the Problem of Incompatible Co-Administration

Methandienone is an orally active 17α-alkylated androgen whose hepatic and cardiovascular burden is substantially amplified when specific co-administered agents are present — making an informed understanding of unfavorable combinations as clinically important as the correct dose itself. The Knoll Pharmaceuticals Danabol 500 pack provides 500 tablets at 10 mg each, a supply volume large enough to span multiple sequential phases; anyone using this quantity needs a concrete framework for what not to combine.

Which Compound Classes Create the Greatest Combined Risk

Stacking two or more 17α-alkylated oral steroids simultaneously is the most consistently flagged unfavorable combination in hepatology case series. Methandienone already elevates serum ALT and AST in a dose-dependent pattern; adding a second alkylated oral — Oxymetholone, Stanozolol, or Oxandrolone — compounds hepatocellular stress along the same enzymatic pathway rather than distributing it across independent mechanisms. Clinical hepatology literature (including peliosis hepatis case reports) identifies concurrent multi-alkylated-oral use as a distinct risk tier above single-agent use. Methandienone combined with prescription hepatotoxins — statins, azole antifungals, or acetaminophen at therapeutic doses — represents a second unfavorable class: each agent competes for CYP-mediated clearance and collectively raises intrahepatic oxidative load beyond any single-compound model.

Cardiovascular and Hormonal Incompatibilities

Compared to Methandienone used alone, the addition of a second strongly aromatizing compound without adequate estrogen management produces supraphysiological estradiol levels that increase left ventricular wall stress and fluid retention concurrently — a combination documented in echocardiographic studies of anabolic steroid users. Methandienone suppresses endogenous testosterone production through hypothalamic–pituitary axis feedback; layering in compounds with deep gonadotropin suppression (high-dose Nandrolone, Trenbolone) before any recovery window extends the suppression period and complicates post-cycle restoration. Alcohol represents a frequently overlooked but pharmacologically active unfavorable co-administration: ethanol and 17α-alkylated steroids share hepatic oxidative metabolism, and the WHO's 2020 liver-disease advisory lists concurrent alcohol use as a contraindication amplifier for any hepatotoxic pharmaceutical.

Practical Monitoring Threshold

Baseline liver-function testing — serum ALT, AST, and GGT — should be established before the first tablet of any 17α-alkylated oral; a two-times-upper-reference-range ALT elevation signals that the current combination load has reached the discontinuation threshold recognized in sports-medicine hepatology protocols.

Usage

Audit your current medication and supplement list for hepatotoxic agents — statins, azole antifungals, acetaminophen above 2 g/day, and any alcohol use — and eliminate or medically manage each before opening the Danabol 500 pack.
Obtain baseline liver-function results (ALT, AST, GGT) and a lipid panel; record the date and values as the reference against which all future monitoring is compared.
Begin at 10 mg per day using a single Knoll Danabol tablet; do not add a second 17α-alkylated oral compound at any point during the cycle.
If a strongly aromatizing injectable is included in the protocol, confirm that an aromatase inhibitor is already on hand before the first tablet — do not wait for symptomatic estrogen excess to appear.
Re-test ALT and AST at weeks two and four; if either exceeds two times the upper reference range, reduce to 10 mg/day immediately and retest within one week before deciding whether to continue.
After the final tablet, enforce a minimum four-week oral-free window before introducing any subsequent 17α-alkylated compound, regardless of how low the final-week dose was.

Warnings

Contraindications: Methandienone is contraindicated in individuals with pre-existing hepatic impairment, cholestatic liver disease, or elevated baseline transaminases (ALT/AST above 1.5× upper reference range). Concurrent use with prescription hepatotoxins — including azole antifungals and HMG-CoA reductase inhibitors (statins) — is a pharmacological contraindication due to compounding CYP-pathway stress. Alcohol consumption during any 17α-alkylated oral cycle is a recognized contraindication amplifier per WHO liver-disease guidance.

Side Effects: Hepatotoxicity is the primary organ-level risk, presenting as elevated ALT and AST; severity scales with dose, duration, and combination load. Estrogenic effects — fluid retention, gynecomastia — intensify when Methandienone is paired with other aromatizing compounds without estrogen management. LDL elevation and HDL suppression are consistent adverse lipid effects; endogenous testosterone suppression occurs via hypothalamic–pituitary axis feedback and deepens with concurrent gonadotropin-suppressing agents.

Monitoring: Liver-function panel (ALT, AST, GGT, bilirubin) at baseline, week two, and week four. Lipid panel at baseline and cycle end. Blood pressure monitoring twice weekly during active use. Any ALT elevation exceeding two times the upper reference range triggers dose reduction; exceeding three times triggers immediate discontinuation.

PCT: Post-cycle therapy timing is governed by the clearance half-life of the longest-acting injectable in the stack, not by Methandienone's own rapid clearance. SERM-based protocols using Tamoxifen or Clomiphene are standard; no second alkylated oral should be introduced during PCT, as this would re-impose hepatic and suppressive burden during the recovery window.

Frequently asked questions

Which oral steroids should never be combined with Methandienone due to liver risk?: No second 17α-alkylated oral should be run concurrently with Methandienone. Compounds such as Oxymetholone, Stanozolol, or Oxandrolone stress the same hepatic enzyme pathways, and hepatology case series consistently identify multi-alkylated-oral stacks as a distinct, higher-risk category. Running them sequentially — not simultaneously — is the standard risk-reduction approach cited in sports-medicine literature.
Does alcohol consumption interact negatively with Methandienone tablets?: Yes — alcohol is a pharmacologically active unfavorable co-administration with Methandienone. Both ethanol and 17α-alkylated compounds compete for hepatic oxidative metabolism, raising intrahepatic oxidative load beyond single-agent predictions. The WHO's 2020 liver-disease guidelines list concurrent alcohol use as a contraindication amplifier for hepatotoxic pharmaceuticals, which includes orally alkylated androgens.
Can prescription medications like antifungals or statins be taken alongside Methandienone safely?: This combination carries measurable added risk. Azole antifungals inhibit CYP3A4, slowing Methandienone clearance and raising systemic exposure; statins independently elevate liver enzymes via hepatic mechanisms distinct from but additive to 17α-alkylation stress. Practitioners using either drug class should consult a physician and monitor ALT, AST, and GGT at closer intervals than during Methandienone-only protocols.
How many tablets does the Knoll Danabol 500 pack contain, and how are they packaged for long-term storage?: The pack contains exactly 500 tablets at 10 mg Methandienone each. Knoll Pharmaceuticals formats this supply in a configuration designed to protect tablet integrity across the extended storage periods that a 500-count volume requires — important because API degradation from humidity or heat would compromise dose accuracy at any point in the supply window.
Can the 10 mg tablets be split for sub-10 mg dosing within an unfavorable-combination avoidance protocol?: Splitting is mechanically possible but pharmacologically imprecise. HPLC content-uniformity testing applies to the intact tablet; a split half carries an unmeasured variance that matters most when the combination context already demands precise exposure management. Where sub-10 mg intake is the goal to reduce combined hepatic load, reducing or discontinuing the tablet is preferable to fractioning it. (2) angle_used

Manufacturer

Knoll Pharmaceuticals operates as a pharmaceutical manufacturing entity with production infrastructure calibrated to tablet-format anabolic compounds — the Danabol 500 line being an example of large-batch oral production at 10 mg per tablet. Manufacturing technology at Knoll encompasses high-precision tablet compression equipment capable of maintaining API uniformity across high-count batches (500 tablets per unit), with HPLC-based content verification applied at the lot level to confirm that per-tablet Methandienone content remains within pharmaceutical variance limits. Batch traceability is maintained from raw API intake through granulation, compression, and packaging, giving practitioners a documentation chain that supports clinical monitoring correlation.

Product details

Brand	Knoll Pharmaceuticals
Active ingredient	methandienone
Also known as	Dianabol, Methandrostenolon, D-Bol, Danabol, Danabol 500, Knoll Pharmaceuticals Dianabol
Strength	10 mg
Form	Tabletten
Pack size	500 pieces
Item number	ORA-METH-KNO-014

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Danabol 10mg/tab 100 Tablets by Balkan Pharmaceuticals

Lab Tested

Danabol 10mg/tab 100 Tabletten by Balkan Pharmaceuticals

Danabol by Balkan Pharmaceuticals is an oral anabolic-androgenic steroid whose active compound, Methandienone (10 mg per tablet), functions as a modified testosterone derivative engineered to bind directly and with notable affinity to the androgen receptor (AR), driving rapid anabolic signalling at the genomic level. Its 17α-alkylated, 2,17-dimethyl structural scaffold distinguishes it from unmodified androgens by increasing receptor-interaction duration and conferring oral bioavailability. Quality assurance for every batch is anchored in two validated analytical checkpoints: HPLC quantification of active-ingredient potency and LAL endotoxin screening — performed under Balkan Pharmaceuticals' certified GMP framework.

€26.00

Pro-Dynabol 20mg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Pro-Dynabol 20mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Dynabol is an oral anabolic tablet delivering Methandienone at 20 mg per unit, distinguished by a rapid-absorption, short-duration pharmacokinetic profile that demands a structured intraday dosing schedule to maintain stable plasma concentrations. Each pack contains 50 tablets, providing a complete supply for a standard introductory or intermediate oral cycle. Batch-level potency is confirmed through HPLC analysis; every lot produced by Beligas Pharmaceuticals passes documented laboratory verification before release.

€35.00

Danabol 10mg/tab 100 Tablets by Body Research

Pharma Grade

Danabol 10mg/tab 100 Tabletten by Body Research

Body Research Danabol delivers Methandienone at 10 mg per tablet across a 100-tablet supply, specifically formulated to maximize the oral bioavailability that distinguishes tablet-based administration from injectable Methandienone variants. Oral Methandienone reaches systemic circulation through hepatic first-pass metabolism, which reduces its absolute bioavailability to roughly 50–72 % compared to the near-complete uptake seen with intramuscular injection — a pharmacological trade-off that makes tablet selection, dosing timing, and gastrointestinal conditions decisive factors. Quality is verified through independent HPLC-based potency assay and LAL endotoxin testing; every production batch released under WHO-aligned GMP protocols reflects Body Research's Pharma Grade standard.

€85.00

Anabol Tablets 5mg/tab 1000 Tablets by British Dispensary

Purity Tested

Anabol Tablets 5mg/tab 1000 Tabletten by British Dispensary

British Dispensary Anabol Tablets deliver Methandienone at a precision-dosed 5 mg per tablet — a low-unit format that makes incremental metabolic titration straightforward for experienced users tracking blood-glucose and nutrient-partitioning responses. Anabolic-androgenic activity from this compound is closely linked to shifts in glucose uptake, glycogen synthesis, and overall substrate utilisation, making metabolic monitoring an integral part of any responsible protocol. Quality assurance is built into every 1,000-tablet jar: HPLC-verified potency and LAL endotoxin testing are completed prior to release, with manufacturing conducted under GMP-certified conditions at British Dispensary's Thailand facility.

€85.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00